Latest Articles
No checkpoint glory for Acrivon | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
No checkpoint glory for Acrivon | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Published: Jan. 12, 2026, 1:11 p.m.
Endometrial Cancer: Framing Prognosis, Weaving Clinical Trials and Real-World Data into Patient Conversations - OncLive
Endometrial Cancer: Framing Prognosis, Weaving Clinical Trials and Real-World Data into Patient Conversations OncLive
Published: Jan. 2, 2026, 1:10 p.m.
Cartherics appoints Dr Ian Nisbet as CEO as the company accelerates toward clinical trials - BiotechDispatch
Cartherics appoints Dr Ian Nisbet as CEO as the company accelerates toward clinical trials BiotechDispatch
Published: Dec. 1, 2025, 11:34 p.m.
S01 E07 - Why weren't women included in clinical trials? - TVO Today
S01 E07 - Why weren't women included in clinical trials? TVO Today
Published: Nov. 11, 2025, 2 p.m.
S01 E07 - Why weren't women included in clinical trials? - TVO
S01 E07 - Why weren't women included in clinical trials? TVO
Published: Nov. 11, 2025, 2 p.m.
Triple meeting 2025 – early efficacy signs for Quanta | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Triple meeting 2025 – early efficacy signs for Quanta | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Published: Oct. 27, 2025, 3:49 p.m.
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability - Clinical Trials Arena
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability Clinical Trials Arena
Published: Oct. 20, 2025, 1:12 p.m.
Genmab takes its Profound buy into endometrial | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Genmab takes its Profound buy into endometrial | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Published: Sept. 16, 2025, 3:39 p.m.
Endometrial Cancer Pipeline Outlook 2025 - Clinical Trials, - openPR.com
Endometrial Cancer Pipeline Outlook 2025 - Clinical Trials, openPR.com
Published: Aug. 20, 2025, 3:46 a.m.
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences The Globe and Mail
Published: Aug. 6, 2025, 1:11 p.m.
Link copied to clipboard!